Boehringer Ingelheim says new studies underline efficacy of lung disease drug

pharmafile | May 18, 2016 | News story | Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease 

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile.

The company said its Ofev (nintedanib) slowed disease progression in Phase III trials for idiopathic pulmonary fibrosis (IPF).

In addition to slowing of disease progression the drug also reduced lung function decline, the company said in a statement.

Imre Noth, director of the interstitial lung disease program at the University of Chicago, said: “Ongoing analyses of the Phase III Inpulsis trials along with real-world data provide additional support for the safety and efficacy of treatment with Ofev. As slowing disease progression is an important treatment goal, these data provide support for the benefit to IPF patients regardless of disease severity.”

IPF is a debilitating and fatal lung disease with high mortality, affecting as many as 3 million people worldwide. Progression of IPF is variable and unpredictable, and over time the lung function of an IPF patient gradually and irreversibly declines. IPF causes permanent scarring or fibrosis of the lung, difficulty breathing and decreases the amount of oxygen the lungs can supply to major organs of the body.

Anjali Shukla

Related Content

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …

Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug

US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed …

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks …

Latest content